Want to see HK:6833 full AI Analyst Report?
Sinco Pharmaceuticals Holdings Ltd. (6833) AI Stock Analysis
Sinco Pharmaceuticals Holdings Ltd.
(HKEX:6833)
The overall score is mainly driven by a cautious financial profile and weak share price trend, reflecting margin compression, revenue decline in 2025, falling returns on equity, and volatile cash flows, while an improved balance sheet, ongoing profitability, and undemanding valuation provide some support and prevent a materially lower rating.
Sinco Pharmaceuticals Holdings Ltd. (6833) vs. iShares MSCI Hong Kong ETF (EWH)
- Market Cap
- HKD 306.97M
- Dividend Yield
- 1.11%
- Average Volume (3M)
- 181.19K
- Price to Earnings (P/E)
- 8.6
- Beta (1Y)
- -0.08
- Revenue Growth
- -20.04%
- EPS Growth
- -25.66%
- Country
- Hong Kong
- Employees
- 257
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Distribution
Sinco Pharmaceuticals Holdings Ltd. Business Overview & Revenue Model
Company Description
Sinco Pharmaceuticals Holdings Limited operates as an investment holding entity primarily specializing in the marketing, promotion, and distribution channel management of imported pharmaceutical products and medical devices throughout China. Its prod...
Sinco Pharmaceuticals Holdings Ltd. Financial Statement Overview
Summary
Score reflects weakening profitability and volatile cash flows, including revenue decline, margin compression, falling ROE, and negative free cash flow in some years, partly offset by a stronger balance sheet and continued overall profitability.
Income Statement
42NeutralBalance Sheet
65PositiveCash Flow
45Neutral| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.92B | 2.08B | 2.82B | 2.54B | 2.27B | 2.02B |
| Gross Profit | 213.81M | 222.09M | 299.94M | 323.28M | 305.87M | 364.95M |
| EBITDA | 90.60M | 99.83M | 138.44M | 126.01M | 112.58M | 199.25M |
| Net Income | 30.39M | 34.85M | 42.05M | 42.35M | 69.46M | 135.08M |
Balance Sheet | ||||||
| Total Assets | 2.11B | 1.85B | 2.00B | 1.89B | 1.42B | 1.23B |
| Cash, Cash Equivalents and Short-Term Investments | 369.41M | 374.53M | 308.32M | 437.92M | 329.14M | 326.05M |
| Total Debt | 116.76M | 183.47M | 350.54M | 251.40M | 192.41M | 340.95M |
| Total Liabilities | 1.40B | 1.15B | 1.34B | 1.26B | 820.52M | 857.88M |
| Stockholders Equity | 710.88M | 694.36M | 662.88M | 628.05M | 603.81M | 374.89M |
Cash Flow | ||||||
| Free Cash Flow | 305.00M | 159.71M | -268.05M | 289.16M | 22.39M | 282.19M |
| Operating Cash Flow | 313.45M | 169.49M | -232.88M | 353.70M | 75.08M | 305.71M |
| Investing Cash Flow | -29.46M | -27.09M | -52.87M | -63.63M | -119.27M | -22.73M |
| Financing Cash Flow | -250.63M | -197.24M | 154.59M | -189.73M | 35.04M | -97.11M |
Sinco Pharmaceuticals Holdings Ltd. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:6833, the sentiment is Neutral. The current price of 0.15 is above the 20-day moving average (MA) of 0.14, above the 50-day MA of 0.15, and below the 200-day MA of 0.17, indicating a neutral trend. The MACD of 0.00 indicates Negative momentum. The RSI at 59.07 is Neutral, neither overbought nor oversold. The STOCH value of 96.55 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HK:6833.
Sinco Pharmaceuticals Holdings Ltd. Peers Comparison
Overall Rating
HK:109965Neutral
HK:260758Neutral
HK:988656Neutral- HK:683352Neutral
HK:111051Neutral
HK:228947Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| HK:1099 | 65Neutral | HKD 50.52B | 6.11 | 8.33% | 4.88% | 2.78% | 7.71% |
| HK:2607 | 58Neutral | HKD 64.52B | 11.88 | 6.64% | 5.88% | 9.12% | -3.22% |
| HK:9886 | 56Neutral | HKD 1.10B | -15.52 | -3.87% | ― | 8.73% | 80.38% |
| HK:6833 | 52Neutral | HKD 304.93M | 8.60 | 4.33% | 1.11% | -20.04% | -25.66% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| HK:1110 | 51Neutral | HKD 227.44M | 16.84 | 1.89% | 8.45% | -13.82% | 112.24% |
| HK:2289 | 47Neutral | HKD 592.92M | 10.83 | 7.70% | 6.26% | 14.25% | 0.83% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| HK:6833 | Sinco Pharmaceuticals Holdings Ltd. | 0.15 | -0.04 | -19.35% | |
| HK:2607 | Shanghai Pharmaceuticals Holding Co Class H | 11.11 | -0.06 | -0.53% | |
| HK:1099 | Sinopharm Group Co Class H | 16.19 | -2.17 | -11.84% | |
| HK:9886 | Dingdang Health Technology Group Ltd. | 0.90 | -0.19 | -17.43% | |
| HK:1110 | Kingworld Medicines Group Ltd. | 0.38 | -0.16 | -29.25% | |
| HK:2289 | Charmacy Pharmaceutical Co., Ltd. Class H | 5.49 | 0.38 | 7.46% |
Sinco Pharmaceuticals Holdings Ltd. Corporate Events
Sinco Pharmaceuticals’ Interim Profit Falls as Revenue Declines Despite Margin Improvement
Sinco Pharmaceuticals reported interim revenue of RMB1.03 billion for the six months ended 30 June 2026, down 13.7% year-on-year, mainly due to weaker sales of pharmaceutical products and a small decline in medical beauty service income. Despite the...
Sinco Pharmaceuticals strengthens board with new independent directors
Sinco Pharmaceuticals Holdings Ltd. has appointed Mr. Dong Yingjie and Mr. Ye Guowei as independent non-executive directors, effective 28 August 2026, strengthening the company’s board oversight and governance structure. The move is expected to...
Sinco Pharmaceuticals Details Board and Committee Structure
Sinco Pharmaceuticals Holdings Limited has announced the current composition of its board of directors, detailing the executive, non-executive and independent non-executive directors, including the chairman and lead independent director. The company...
Sinco Pharmaceuticals Sets August Board Meeting to Review Interim Results and Dividend
Sinco Pharmaceuticals Holdings Limited has scheduled a board meeting for 28 August 2026 to review and approve the interim results of the company and its subsidiaries for the six months ended 30 June 2026. The board will also consider whether to recom...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Sep 18, 2026